Hands holding up auction bidding paddles.
- Eidos Therapeutics (NASDAQ:EIDX) has received a non-binding proposalfrom BridgeBio Pharma (NASDAQ:BBIO) to acquire the rest of the company that it does not already own (~2/3 of its outstanding shares). Under the terms of the proposal, BBIO would acquire the stock at a fixed ratio of 1.30 BBIO shares for each EIDX share.
- The board has formed a special committee to consider the offer.
Date: August 13, 2019
Source: Flipboard
